[ad_1]
JAKARTA, (PR) .- The bad cancer drug "Trastuzumab Subcutan" may be an alternative to other cancer drugs, Trastuzumab Intraven. As reported by Antara News Agency, Ph.D. in Hematology-Medical Oncology from Dharmais Cancer Hospital Dr. Nugroho Prayogo, SpPD-KHOM in Jakarta, Wednesday, July 11, 2018, Trastuzumab subcutaneously saves time on the care provided in hospitals specializing in cancer treatment and in pharmacies, so that there is a better practical opportunity, which saves time, "says Nugroho
.When intravenous trastuzumab is administered intravenously and takes 30 to 90 minutes, trastuzumab subcutaneously takes only 2 to 5 minutes.
Dr. Diah Ayu Puspandari Apt, Mr. Director of the Health and Management Center of the University of Kes health insurance said that the subcutaneous administration of trastuzumab can reduce the waiting time of patients without interacting with the clinician .26% and clinical treatment time of 58%.
On the basis of his studies , hospitals can also benefit from maintenance savings of up to 35% per patient per year. Diah explained that savings are calculated on direct costs
Do not leave the rest of the dose
Hospital Nurse Dr. Soetomo Surabaya Zr Musrini who has more than 20 years of experience with cancer patients revealed subcutaneous trastuzumab is very helpful In addition to the provision of trastuzumab that does not need to be hospitalized first, Musrini said that the administration of subcutaneous traztuzumab could not cause swelling or injury.
Meanwhile, according to him, intravenous trastuzumab can cause the extravasation of cancer drugs. through wounds.
Intravenous trastuzumab requires a mixture of liquid in pharmaceuticals and must be mixed in intravenous fluids which are then injected into the patient's veins. However, the administration of subcutaneous trastuzumab was administered by injection into the upper thigh
. The use of subcutaneous trastuzumab also did not require further treatment such as intravenous trastuzumab
BPOM
The subcutaneous trastuzumab is currently available in Indonesia obtained the approval of the Food and Drug Monitoring Agency (BPOM) on May 23, 2018.
The approval of this subcutaneous trastuzumab is excellent news for patients as the process global administration is faster. In addition to saving resources in health staff, improving patient care capacity and saving on hospital operating costs, Binay Swarup, Roche's medical director Medical, stated:
and guaranteed in the services of Jamin National Health BPJS Health
Roche is working on subcutaneous trastuzumab to enter a national form in order to be used as a drug for BPJS participants Health. Trastuzumab subcutaneously is also less expensive than intravenous trastuzumab. ***
[ad_2]
Source link
